Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib and FDG-PET in Recurrent EGFR-Activated Glioblastoma
NCT03732352Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Nov 2018
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in glioblastoma (GBM), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Intrapatient variance of tumor fludeoxyglucose F-18 (FDG) uptake and Change in FDG uptake in tumor. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03732352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732352.